Low response to a monovalent inactivated unadjuvanted influenza A (H1N1) pdm09 vaccine in pediatricians of a general hospital in Japan

Figures & data

Table 1. Characteristics of staff and pandemic influenza A (H1N1) 2009 and Seasonal Influenza vaccination coverage

	Total number of staff	Pandemic A(H1N1)2009 vaccinated subject number	Pandemic A(H1N1)2009 vaccination rate (%)	Seasonal influenza vaccinated subjects	Seasonal influenza vaccination rate (%)
Overall vaccination 2008–2009	1,191	0	0	1,035	86.9
Overall vaccination 2010–2011	1,247	1,072	86.0	1,072	86.0
Overall vaccination 2009–2010	1,226	904	73.7	1,071	87.4
All healthcare professionals	1,134	830	73.2	991	87.4
Physicians (except pediatricians) Pediatricians	232 18	163 17	70.3 94.4	179 17	77.2 94.4
Total number of medical doctors	250	180	72.0	196	78.4
Nurses and nursing assistants	692	494	71.4	625	90.3
Pharmacists	27	22	81.5	22	81.5
Technicians	192	152	79.2	170	88.5
Administrative personnel	92	74	80.4	80	87.0

Table 2. Immune responses, geometric mean titers and fold increases in geometric mean titers, as measured using hemagglutination inhibition (HI) assay after first and second vaccinations with the pandemic influenza a (H1N1) 2009 vaccine

[Reference No.] group age	Group A 27–34 y (n = 10)	Group B 35–49 y (n = 6)	Total 27–49 y (n = 16)	[12] HCP 21–58 y (n = 98)	[13] HCP A 20–29 y (n = 120)	[13] HCP B 30–69 y (n = 268)	[13] HCP total 20–69 y (n = 389)	[14] HCP N.D. (n = 51)	[19] HCP A 20–40 y (n = 50)	[19] HCP B 41–64 y (n = 50)	[19] HCP total 20–64 y (n = 100)	[20] HCP 21–56 y (n = 98)
Seroprotection rate (95% C.I.)
Day 0	10.0 (-12.6, 32.6)	0.0 (0.0, 0.0)	6.3 (-7.1, 19.6)	8.2 (2.7, 13.7)	5.0 (1.0, 8.9)	2.2 (0.5, 4.0)	3.1 (1.4, 4.8)	61 (47.6, 74.4)	44 (30, 58.7)	42 (28.2, 56.8)	43 (31.9, 54.7)	9 (N.D.)
Day 21	70.0 (35.4, 104.5)	0.0 (0.0, 0.0)	43.8 (16.4, 71.1)	78.6 (70.3, 86.8)	45.5 (36.5, 54.5)	34.7 (29.0, 40.0)	38.0 (33.2, 42.9)	96 *1 (96.6, 101.4)	100 (92.9, 100)	100 (92.9, 100)	100 (95.7, 100)	97 (N.D.)
5 mo	80.0 (49.8, 110.2)	0.0 (0.0, 0.0)	50.0 (22.5, 77.5)	N.D.	N.D.	N.D.	N.D.	N.D.	100 *2 (92.9, 100)	100 *2 (92.9, 100)	100 *2 (95.7, 100)	84
Seroconversion rate (95% C.I.)
Day 21	70.0 (35.4, 104.6)	0.00 (0.00, 0.00)	43.8 (16.5, 71.1)	73.5 (63.6, 81.9)	40.5 (31.6, 49.4)	32.1 (26.5, 37.7)	34.7 (30.0, 39.5)	59 *1 (45.5, 72.5)	100 (92.9, 100)	88 (75.7, 95.5)	94 (86.4, 98.1)	88 (N.D.)
5 mo	70.0 (35.4, 104.6)	0.00 (0.00, 0.00)	43.8 (16.5, 71.1)	N.D.	N.D.	N.D.	N.D.	N.D.	100 *2 (92.9, 100)	100 *2 (92.9, 100)	100 *2 (95.7, 100)	75
GMT (95% C.I.)
Day 21	10.7 (7.4, 15.6)	8.9 (7.1, 11.2)	10.0 (7.8, 12.8)	7.9 (6.8, 9.2)	7.0 (6.2, 7.8)	6.1 (5.8, 6.5)	6.4 (6.1, 6.7)	45.8 (37.2, 67.3)	8.9 (7.1, 11.1)	8.6 (6.8, 10.9)	8.8 (7.3, 10.5)	7.7 (6.8, 8.7)
5 mo	56.6 (27.8, 114.9)	8.9 (7.10, 11.2)	27.1 (14.1, 52.2)	73.5 (56.0, 96.4)	28.0 (22.4, 35.0)	20.1 (17.6, 22.8)	22.3 (19.9, 24.9)	196 *1 (146.0, 263.5)	258.3 (191.3, 348.7)	205.3 (145.4, 290)	230.3 (177.7, 298.4)	435.8 (367.7, 516.5)
GMT fold increase (95% C.I.)
	42.9 (24.7, 74.5)	15.9 (10.1,25.0)	29.5 (18.9, 46.2)	N.D.	N.D.	N.D.	N.D.	N.D.	505.6 *2 (427.9, 597.6)	465.3 *2 (384.5, 563)	485 *2 (420.3, 559.7)	160.8 *3 (124.6, 118.6)
Day 21	8.0 (3.0, 13.0)	1.0 (1.0, 1.0)	5.4 (1.9, 8.8)	9.3 (7.3, 11.9)	4.0 (0.4, 36)	3.3 (3.3, 4.9)	3.3 (3.3, 4.9)	4.3 *1 (3.0, 6.1)	29.1 (21.8, 38.9)	3.3 (3.3, 4.9)	3.5 (3.1, 3.9)	113.8 (71.4, 156.2)
5 mo	5.3 (21, 8.5)	1.8 (0.2, 2.3)	4.0 (6.0, 2.0)	N.D.	N.D.	N.D.	N.D.	N.D.	57 *2 (44.3, 73.2)	23.8*2 (17.4, 32.6)	53.9*2 (42.6, 68.1)	99.5*3 (32.0, 166.9)

EMA: seroprotection rate > 70%; seroconversion rate > 40%; GMT fold (95% C.I.) > 2.5; *N.D., not described; *1, day 14; *2, day 42; *3, 3 mo.